RECIST Response Criteria
RECIST (Response Evaluation Criteria in Solid Tumors) is a standardized unidimensional measurement system that defines tumor response based on changes in the sum of longest diameters of target lesions: ≥30% decrease for partial response, ≥20% increase for progression, and intermediate changes for stable disease 1.
Core Measurement Principles
RECIST fundamentally differs from older WHO criteria by using unidimensional measurements (longest diameter only) rather than bidimensional measurements 1. This simplification was validated in over 4,000 patients across 14 studies, demonstrating that one-dimensional versus two-dimensional measurements did not alter response rates 1.
Lesion Measurability Requirements
Lesions qualify as measurable when:
- ≥2 cm with conventional imaging techniques
- ≥1 cm with spiral CT scan 1
Target vs. Non-Target Lesions
The system divides tumor burden into two categories:
Target lesions: Pre-selected measurable lesions (up to 10 total) that represent overall tumor load and are measured serially 1. Research suggests measuring just 2 lesions produces excellent concordance with measuring all lesions, with response rates differing by no more than 3% 2.
Non-target lesions: All other lesions (measurable and non-measurable) are recorded but not measured, assessed qualitatively 1, 3.
Response Categories
Complete Response (CR)
Disappearance of all target lesions
Partial Response (PR)
≥30% decrease in sum of longest diameters of target lesions 1
- Must be confirmed after minimum 4-week interval 1
Progressive Disease (PD)
≥20% increase in sum of longest diameters of target lesions, OR
- Non-equivocal progression in non-target lesions, OR
- Appearance of any new lesion 1
Stable Disease (SD)
Changes insufficient to qualify as PR or PD
- Requires two evaluations separated by protocol-specific interval 1
Critical Implementation Details
Imaging method specifications: RECIST provides precise guidance on which imaging modalities can be used and how measurements should be performed 1.
Combining target and non-target results: Specific algorithms exist for determining overall response when target and non-target lesions show discordant patterns 1.
Best overall response: Guidelines clarify how to interpret successive evaluations to define the best response achieved during treatment 1.
Special Considerations
Ovarian cancer exception: CA125 alone may determine progression after first-line treatment in advanced ovarian cancer 1.
Tumor-specific adaptations: Modified RECIST criteria exist for brain tumors, mesothelioma, pelvic tumors, non-Hodgkin's lymphoma, and prostate cancer 1.
Common Pitfalls
The 20% threshold for progression requires a larger absolute change than the older WHO 25% criterion, potentially resulting in slightly lower progression rates 1. Non-target lesion assessment remains somewhat subjective and prone to errors at baseline and follow-up 3.
Important limitation: RECIST has recognized limitations in precision cancer therapy and immunotherapy settings, where alternative criteria (like immune-related RECIST) may be more appropriate 4, 5.